Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Intensive integrated therapy of type 2 diabetes : implications for long-term prognosis. / Gaede, Peter; Pedersen, Oluf.
In: Diabetes, Vol. 53 Suppl 3, 2004, p. S39-47.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Intensive integrated therapy of type 2 diabetes
T2 - implications for long-term prognosis
AU - Gaede, Peter
AU - Pedersen, Oluf
PY - 2004
Y1 - 2004
N2 - The macro- and microvascular burden of type 2 diabetes is well established. A number of recent single risk factor intervention trials targeting hyperglycemia, dyslipidemia, hypertension, procoagulation, microalbumuria, and existing cardiovascular disorders have, however, shown major beneficial effects on long-term outcome. The results from these studies are anticipated to change the future management of type 2 diabetes, and most of the updated national guidelines for the treatment of type 2 diabetes recommend a multipronged approach driven by ambitious treatment targets. The outcome of this intensive integrated therapy has, however, only been investigated in a few studies of patients with type 2 diabetes. One of these trials, the Steno-2 Study, showed that intensive intervention for an average of 7.8 years cuts cardiovascular events as well as nephropathy, retinopathy, and autonomic neuropathy by about half when compared with a conventional multifactorial treatment. The challenge for now is to ensure that the trial experiences are widely adopted in daily clinical practice.
AB - The macro- and microvascular burden of type 2 diabetes is well established. A number of recent single risk factor intervention trials targeting hyperglycemia, dyslipidemia, hypertension, procoagulation, microalbumuria, and existing cardiovascular disorders have, however, shown major beneficial effects on long-term outcome. The results from these studies are anticipated to change the future management of type 2 diabetes, and most of the updated national guidelines for the treatment of type 2 diabetes recommend a multipronged approach driven by ambitious treatment targets. The outcome of this intensive integrated therapy has, however, only been investigated in a few studies of patients with type 2 diabetes. One of these trials, the Steno-2 Study, showed that intensive intervention for an average of 7.8 years cuts cardiovascular events as well as nephropathy, retinopathy, and autonomic neuropathy by about half when compared with a conventional multifactorial treatment. The challenge for now is to ensure that the trial experiences are widely adopted in daily clinical practice.
KW - Algorithms
KW - Behavior Therapy
KW - Diabetes Mellitus, Type 2
KW - Family Practice
KW - Humans
KW - Hypoglycemic Agents
KW - Prognosis
KW - Time Factors
M3 - Journal article
C2 - 15561920
VL - 53 Suppl 3
SP - S39-47
JO - Diabetes
JF - Diabetes
SN - 0012-1797
ER -
ID: 38457030